HeidelbergerC., ChaudariN.K., DannebergP.: Fluorinated pyrimidine. A new class of tumor inhibitory compounds. Nature, 179: 663–666, 1957.
2.
GebbiaV., TestaA., BorsellinoN., CannataG., ValenzaR., GebbiaN.: Pharmacological modulation of 5-fluorouracil and its clinical implications: an overview. In Vivo, 7(6B): 639–644, 1993.
3.
FujiiS., IkenakaK., FukushimaM.: Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil. Gan To Kagaku Ryoho, 69: 763–772, 1978.
4.
PazdurR.: Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin. Oncology, 11(Suppl. 10): 35–39, 1997.
5.
Gonzalez-BaronM., FeliuJ., de la GandaraI., EspinosaE., ColmenarejoA., Martinez-MartinezB., BlancoE., Garcia-GironC., JuarezF., GarridoP., OrdonezA., ZamoraP.: Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur. J. Cancer, 31: 2215–2159, 1995.
6.
CaoS., RustumY.M., SpectorT.: 5-ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res., 54: 1507–1510, 1994.
7.
CzejkaM.J., JagerW., SchullerJ.: Clinical pharmacology of 5-fluorouracil, influence of the biomodulating agents interferon, dipyridamole and folinic acid alone and in combination. Arznelmirtelforschung, 43: 387–390, 1993.
8.
ShirasakaT., ShimamatoY., OhshimoH., YamaguchiM., KatoT., YonekuraK., FukushimaM.: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs, 7: 548–557, 1996.
9.
PetersG.J., Van GroeningenC.J., SchomageJ.H., GallH.E., NoordhuisP., de VriesandM., Van KullenburgandA.B., HanauskeA.R.: Phase I clinical and pharmacokinetic study of S-1, an oral 5-fluorouracil (5-FU)-based antineoplastic agent. Proc. Am. Soc. Oncol., 16: A800, 1997.
10.
TaguchiT., HorikoshiN., KinoshitaH., TogeT., TakashimaS.: Early phase II study of S-1 in patients with advanced breast cancer. Proc. Am. Soc. Clin. Oncol., 15: A151, 1996.
11.
OkaysuT., SugiyamaK., MiyauchiS.: Inhibition of catabolic pathway of 5-fluorouracil by 3-cyano-2,6-dihydroxypyridine in human lung cancer tissues. Gan To Kagaku Ryoho, 85: 101–105, 1994.
12.
IshitsukaH., MiwaM., IshikawaT., UraM., SawadaN., NishidaM., FukaseY., YamamotoT., MoriK., ArasakiM.: Capecitabine: an orally available fluoropyrimidine with tumor selective activity. Proc. Am. Soc. Clin. Oncol., 36: A2426, 1995.
13.
SchullerJ., CassidyJ., ReignerB.G., DurstonS., RoosB., IshitsukaH., UtohM., DumontE.: Tumor selectivity of Xeloda in colorectal cancer patients. Proc. Am. Soc. Clin. Oncol., 16: A797, 1997.
14.
RustumY.M., HarstrickA., CaoS., VanhoeferU., YinM.B., WilkeH., SeeberS.: Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J. Clin. Oncol., 15: 389–400, 1997.
15.
KinahanJ.J., OttenM., GrindeyG.B.: Evaluation of ribonucleoside and deoxyribonucleoside triphosphate pools in cultured leukemia cells during exposure to methotrexate or methotrexate plus thymidine. Cancer Res., 39: 3531–3539, 1979.
16.
MoranR.G.: Roles of folypoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Sem. Oncol., 26: 24–32, 1999.
17.
MicetichK.C., BarnesD., EricksonL.C.: A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino) (1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells. Cancer Res., 45: 4043–4047, 1985.
18.
MoreauS., MachoverD., de GramontA., GastiaburuJ., BrienzaS., LouvetC., VaretteC., KrulikM., MissetJ.L.: Phase II trial of oxaliplatin (L-OHP) in patients with colorectal carcinoma (CRC) previously resistant to 5-fluorouracil (5-FU) and folinic acid (FA). Proc. Am. Soc. Clin. Oncol., 12: A645, 1993.
19.
AlvarezM., OrtuzarW., RixeO.M., ParkerR., ReedE., FojoT.: Cross-resistance patterns of cell lines selected with platinum suggest differences in the activities and mechanisms of resistance of platinum analogs. Proc. Am. Soc. Clin. Oncol., 35: A2616, 1994.
20.
DeSimoneP.A., DavilaE., JochimsenPR., BartolucciA.A.: High-dose cisplatin in the treatment of advanced adenocarcinoma of the colon and rectum: a Southeastern Cancer Study Group trial. Cancer Treat. Rep., 70: 1229–1230, 1986.
21.
WisemanL.R., AdkinsJ.C., PloskerG.L., GoaK.L.: Oxaliplatin: a review of its use in the management of metastatic colorectal cancer. Drugs Aging, 14: 459–475, 1999.
22.
LeviF., ZidaniR., BrienzaS., DogliottiL., PerpointB., RotarskiM., LetourneauY., LloryJ.F., CholletP., Le RolA., FocanC.: A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Cancer, 85: 2532–2540, 1999.
